SARS-CoV-2 Spike RBD (Wild type)

<strong>SARS-CoV-2 Spike RBD (Wild type)</strong>_x000D_ <strong>Catalog number:</strong> B2010505_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 27 kDa_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular component of many serological and antigenic assays for SARS-CoV-2_x000D_ <strong>Storage:</strong> -20℃_x000D_ <strong>Keywords:</strong> Spike RBD, S1 RBD, Wild Type RBD_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L,_x000D_ Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the_x000D_ ACE2 receptor. Nature. 2020 May;581(7807):215-220._x000D_ _x000D_ 2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312._x000D_ _x000D_ 3: Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin_x000D_ AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP Jr,_x000D_ Bjorkman PJ. SARS-CoV-2 neutralizing antibody structures inform therapeutic_x000D_ strategies. Nature. 2020 Dec;588(7839):682-687._x000D_ _x000D_ 4: Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY,_x000D_ Wang Q, Zhou H, Yan J, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry_x000D_ by Using Human ACE2. Cell. 2020 May 14;181(4):894-904.e9._x000D_ _x000D_ 5: Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus_x000D_ spike protein. J Clin Pathol. 2020 Jul;73(7):366-369._x000D_ _x000D_ 6: Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche_x000D_ CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi_x000D_ N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya_x000D_ P, Haynes BF, Korber B, Montefiori DC. D614G Spike Mutation Increases SARS CoV-2_x000D_ Susceptibility to Neutralization. Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4._x000D_ _x000D_ 7: Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK,_x000D_ Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE,_x000D_ Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE Jr, Bloom_x000D_ JD. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding_x000D_ Domain that Escape Antibody Recognition. Cell Host Microbe. 2021 Jan_x000D_ 13;29(1):44-57.e9._x000D_ _x000D_ 8: Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, Bullock TA, McGary HM, Khan JA,_x000D_ Razmpour R, Hale JF, Galie PA, Potula R, Andrews AM, Ramirez SH. The SARS-CoV-2_x000D_ spike protein alters barrier function in 2D static and 3D microfluidic in-vitro_x000D_ models of the human blood-brain barrier. Neurobiol Dis. 2020 Dec;146:105131._x000D_ _x000D_ 9: Othman H, Bouslama Z, Brandenburg JT, da Rocha J, Hamdi Y, Ghedira K, Srairi-_x000D_ Abid N, Hazelhurst S. Interaction of the spike protein RBD from SARS-CoV-2 with_x000D_ ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor_x000D_ polymorphism. Biochem Biophys Res Commun. 2020 Jun 30;527(3):702-708._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32907861/">10: Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE,_x000D_ Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker_x000D_ D. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020_x000D_ Oct 23;370(6515):426-431. </a>_x000D_ _x000D_ <strong>Products Related to SARS-CoV-2 Spike RBD (Wild type)</strong><a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>